Journal of Clinical Oncology
Articles in this Issue
Trends and disparities in diabetes-associated cancer mortality in the United States, 1999–2020.
11190 Background: Diabetes mellitus (DM) is increasingly recognized as an important contributor to cancer mortality, yet l...
Individualizing first-line treatment choices in metastatic urothelial carcinoma (mUC): Results from a cross-sectional study of physicians in Europe.
e16579 Background: The expanding first-line (1L) treatment options for mUC have introduced complexity to therapy selection...
Failure-to-rescue following major surgical complications in gynecologic oncology: A National Inpatient analysis.
e23124 Background: Postoperative complications are common after major gynecologic oncology surgery, yet mortality is not i...
Retrospective study on safety and efficacy of hypofractionated versus conventional fractionated sequential radiotherapy for stage III unresectable non-small cell lung cancer.
e20058 Background: Large-scale clinical data directly comparing hypofractionated radiotherapy (HypoRT) with conventional f...
Association of omentectomy with reduced therapeutic efficacy of lenvatinib plus pembrolizumab in patients with endometrial cancer.
e17613 Background: Recently, omentum has been suggested to be immunologically active. Therefore, we investigated the effec...
Inpatient chemotherapy in lung cancer: Survival outcomes in small cell and non–small cell lung cancer.
e20592 Background: Patients who receive initial chemotherapy in the palliative setting while inpatient generally have a po...
Effectiveness of first-line ET+CDK4/6i continuation beyond disease progression in a large cohort of patients with HR+/HER2− advanced breast cancer: Results from the multicenter, real-world, Italian study PALMARES-2.
1017 Background: Endocrine therapy (ET) plus Cyclin-Dependent Kinase 4/6 inhibitors (CDK4/6i) is the standard 1...
ZAMBONI: A phase II study of zanzalintinib for metastatic clear cell renal cell carcinoma with bone metastases previously treated with immune checkpoint inhibitors.
TPS4634 Background: Bone metastases (BM) in metastatic renal cell carcinoma (mRCC) are associated with aggressive disease...
A retrospective cohort studying integrative palliative care in a community oncology practice: Impact and outcomes.
12047 Background: Embedding palliative care within oncology practice supports symptom management and shared decision-makin...
Measuring KEYNOTE-522 response from TNBC patient biopsies ex vivo using the E-slice assay.
1132 Background: The KEYNOTE-522 regimen demonstrated a significant survival advantage of adding neoadjuvant pembrolizumab...
Preclinical study on the efficacy of CD4/TGF-β bispecific antibody (MR001) and temozolomide combination therapy for the treatment of multiple metastatic melanoma based on MagIC-PDX model.
e14504 Background: Advanced melanoma remains therapeutically challenging due to drug resistance, metastasis, and an immuno...
Real-world overall survival outcomes of BTK inhibitors vs. venetoclax-based therapy as second-line treatment for chronic lymphocytic leukemia.
7052 Background: Chronic lymphocytic leukemia (CLL) is a B-cell malignancy with highly variable clinical behavior. The tre...
Real-world efficacy and safety of bispecific antibody ivonescimab-based regimens in EGFR-TKI–resistant advanced NSCLC.
8577 Background: Ivonescimab is a first-in-class bispecific monoclonal antibody targeting programmed cell death protein 1...
First-line treatment of QLS31905 plus chemotherapy in patients with pancreatic cancer and gastric cancer: Data from a phase 1b/2 study.
4003 Background: QLS31905, a Claudin18.2/CD3 bispecific antibody, showed manageable safety and encouraging efficacy in Cla...
Emerging trends in research strategies in the first-line recurrent or metastatic head and neck cancer (R/M SCCHN) landscape: A top-level analysis by Oncofocus.
e18029 Background: The current standard of care (pembrolizumab ± platinum-based chemotherapy and cetuximab + platinum-base...
Postpartum-associated breast cancer: Patient outcomes analysis.
e12697 Background: Postpartum-associated breast cancer (PABC) has been defined clinically as breast cancer (BC) diagnosed...
Predicting survival and treatment compliance of cancer patients enrolled in medication access programs across 20 countries.
e13514 Background: Cancer treatment access programs operate worldwide. This study applied classical and machine learning m...
First-in-human dose-escalation study of the selective EGFR/HER2 exon 20 inhibitor PFL-721 in patients with locally advanced or metastatic NSCLC.
8619 Background: PFL-721 is a highly selective, orally bioavailable tyrosine kinase inhibitor (TKI) targeting activating E...
National trends in melanoma-related hospitalizations, admission characteristics, and in-hospital outcomes in the United States, 2018–2022.
e21573 Background: Melanoma remains the most lethal form of skin cancer and contributes substantially to inpatient morbidi...
Spatial architecture of tenascin-c–driven ECM–immune niches in sarcoma.
e23562 Background: Tenascin-C (TNC) is an extracellular matrix glycoprotein highly expressed during embryogenesis but larg...
Geographical heterogeneity in modeled CA-125 KELIM values: Insights from more than 50,000 real-world calculations on the Biomarker Kinetics platform.
5550 Background: The modeled CA-125 KELIM is a pragmatic indicator of primary tumor chemosensitivity during neoadjuvant (N...
Continued CNS-penetrant TKI therapy with or without local CNS therapy after brain metastasis diagnosis in NSCLC.
2036 Background: Patients with oncogene-driven metastatic non–small cell lung cancer (NSCLC) treated with CNS-penetrant ty...
Pre-lymphodepletion CRP and ferritin risk stratification as a predictor of early immune toxicities and hematologic complications after CAR-T therapy: A propensity-matched cohort study.
7030 Background: Inflammation before CAR-T has been linked to higher rates of immune effector cell-associated toxicities a...
Adebrelimab combined with concurrent chemoradiotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: A prospective, single-arm clinical trial.
e16139 Background: The prognosis for patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC) remains p...
Comparative safety and efficacy of trastuzumab deruxtecan (T-DXd) in HER2-positive and HER2-low gastrointestinal malignancies: A systematic review and meta-analysis.
e16337 Background: Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate approved for HER2-positive gastrointestina...